Advancing the science, methodology, and regulatory framework of cancer drug development.

The AAADV Workshop Foundation is a 501(c)(3) nonprofit convening clinical investigators, regulators, industry leaders, biostatisticians, and patient advocates at the forefront of oncology drug development. Now in its third decade, our annual workshop is one of the field's most influential global forums.

Join us November 5–6, 2026 in Bethesda, MD — in-person and virtual.

2026 Workshop Information
2026 Workshop Agenda

New in 2025: the AAADV Workshop Foundation

In 2025, the program reorganized as a 501(c)(3) public charity to broaden access through unrestricted educational grants, expand virtual participation, and deliver year-round educational programming in collaboration with the Triangle Center of Excellence in Regulatory Science and Innovation.

Read more about the Foundation →

2026 Workshop Agenda

Who attends the AAADV Workshop

The AAADV Workshop convenes the people who actually shape oncology drug development:

  • Clinical and translational investigators developing new anticancer agents
  • Regulators from the FDA, EMA, PMDA, NMPA, and other authorities
  • Pharmaceutical and biotech industry leaders
  • Biostatisticians and methodologists working on novel trial designs
  • Patient advocates whose voices anchor the conversation
  • Early-career investigators in academia and industry

Whether your work is in rare cancers, pediatric cancers, immunotherapies, cell and gene therapies, radiopharmaceuticals, or the molecular subtypes of common cancers, the AAADV Workshop offers a candid, multi-stakeholder forum found nowhere else in oncology.

2026 Workshop Information
2026 Workshop Agenda

Scholarships covering the cost of registration, travel and accommodations for the Pre-Workshop for Patient Advocate attendees are available.

Click here for a scholarship application.

Participants Will:​

  • Examine the most urgent issues and meaningful trends in anticancer agent development and validation.
  • Learn new approaches for diagnosing, treating and preventing cancer.
  • Benefit from a mix of small group lectures, moderated discussions, facilitated case studies of successful new drug applications and plenary lectures.
  • Network with researchers, regulators, patient advocates and others working on the front lines of cancer research and treatment.
  • Have access to video recorted sessions and material. 

Special Features

Case studies of successful new drug applications feature pharmaceutical drug development teams and U.S. Food and Drug Administration officers involved in the drug approval process. Four drugs will be presented twice over the course of the Workshop.

The AAADV Workshop In-Depth Discussion Groups offer moderated sessions on numerous topics, each presented by a panel including researchers from academia, industry and the U.S. Food and Drug Administration, as well as patient advocates, giving attendees a rare opportunity to interact with and question numerous experts in a given field of study. Attendees will choose one of five topics, presented concurrently, to attend each day.
 
 
 
 
 

The Core Curriculum is designed for early-career drug development investigators and covers all aspects of clinical studies: pre-clinical and clinical science, statistical structure of trials, ethical requirements and regulatory considerations. It is taught by U.S. Food and Drug Administration (FDA) medical officers and senior scientists.

The 2026 AAADV Workshop Program Committee

Renzo Canetta, MD

Renzo Canetta, MD

(Chair)

H. Kim Lyerly, M.D.

H. Kim Lyerly, MD

AAADV Chair
Duke University

Tom Fleming

Thomas Fleming, PhD

Professor, Department of Biostatistics University of Washington School of Medicine

Richard L. Schilsky

Richard Schilsky, MD

Professor emeritus
University of Chicago

Scott Evans, PhD

Scott Evans, PhD

Elad Sharon, MD

Elad Sharon, MD

Terrell Baptiste

Terrell Baptiste

Dr. Jaap Verweij

Jaap Verweij, MD, PhD

Vivek Subbiah, MD

Vivek Subbiah, MD

Lola Fashoyin-Aje

Lola Fashoyin-Aje, MD, MPH

2026 PROGRAM COMMITTEE

Renzo Canetta, MD (Chair)
H. Kim Lyerly, MD
Thomas Fleming, PhD
Richard L. Schilsky, MD
Scott Evans, PhD
Elad Sharon, MD
Terrell Baptiste
Jaap Verweij, MD, PhD
Vivek Subbiah, MD
Lola Fashoyin-Aje, MD, MPH

AAADV WORKSHOP FOUNDATION BOARD

H. Kim Lyerly, MD
Renzo Canetta, MD
Richard L. Schilsky, MD
Thomas Fleming, PhD
Scott Evans, PhD
Peter Marks, MD, PhD
Susan Galbraith, MB, BChir, PhD
Eric Rubin, MD

From the Program Committee

“The 2026 program reflects what the AAADV Workshop has always done best — convening the people who actually make oncology drug development work, and giving them the space to talk candidly about what is working, what is not, and what comes next. This year’s agenda, from multi-regional trials through dose optimization and the lessons of Complete Response Letters, is built for the reality of modern cancer therapeutics.”

2026 Sponsors

Youtube